Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease

Liver International

Volumn 27, Issue 2, 2007, Pages 215-219

  Mendez Sanchez, N ^a,b   Zamora Valdes, D ^a   Pichardo Bahena, R ^b   Barredo Prieto, B ^b   Ponciano Rodriguez, G ^c   Bermejo Martinez L ^d   Chavez Tapia, N C ^a   Baptista Gonzalez H A ^d   Uribe, M ^a  

^a Department of Biomedical Research Gastroenterology and Liver Unit ^*  (Mexico)

^b LIVER RESEARCH UNIT   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

Endocannabinoids; Liver; Nonalcoholic fatty liver disease

Indexed keywords

BETA ACTIN; CANNABINOID 2 RECEPTOR; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; STATISTICAL SIGNIFICANCE; FATTY LIVER; GENETICS; HEPATITIS; LIVER; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; TISSUE DISTRIBUTION;

FATTY LIVER; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; PROSPECTIVE STUDIES; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 34247579754     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01401.x     Document Type: Article

References (23)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
2. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-63.
3. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
4. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
5. Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J Pharmacol Sci 2004; 96: 367-75.
6. Osei-Hyiaman D, Depetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-305.
7. Biswas K K, Sarker KP, Abeyama K, et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003; 38: 1167-77.
8. Gabbay E, Avraham Y, Ilan Y, Israeli E, Berry EM. Endocannabinoids and liver disease-review. Liver Int 2005; 25: 921-6.
9. Zamora-Valdes D, Ponciano-Rodriguez G, Chavez-Tapia NC, Mendez-Sanchez N. The endocannabinoid system in chronic liver disease. Ann Hepatol 2005; 4: 248-54.
10. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006; 29: 58-65.
11. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-6.
12. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-55.
13. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
14. Caramelo C, Fernandez-Gallardo S, Santos JC, et al. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest 1987; 17: 7-11.
15. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988; 8: 232-6.
16. Berdyshev EV, Schmid PC, Krebsbach RJ, Schmid HH. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 2001; 15: 2171-8.
17. Liu J, Batkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003; 278: 45034-9.
18. Fernandez-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004; 24: 477-83.
19. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem (Tokyo) 2004; 135: 517-24.
20. Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids. J Cell Biochem 2001; 81: 715-23.
21. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 2000; 406: R5-7.
22. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005; 41: 1085-95.
23. Gokoh M, Kishimoto S, Oka S, et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem J 2005; 386: 583-9.